Read our Recent Headlines


Mar 21, 2019 by Dave Sobek

March 21 Biotech Update

This will certainly be a bad day for the large cap but I would not be surprised to see the XBI outperform if not eventually turn green as M&A fever.

Share 0 Comments Read more
Mar 19, 2019 by Dave Sobek

March 19th Biotech Update

The XBI seems to be churning early this week and while we did not get the run that was possible, it is not bad to sit at these levels for.

Mar 14, 2019 by Dave Sobek

March 14 (Pi day) biotech update

A nice late day rally yesterday was a good sign. That was what I was waiting for after a morning of listless direction. It is looking more and more likely.

Mar 13, 2019 by Dave Sobek

March 13 Biotech Update

Yesterday was a good day for the sector and we are right back to what could be some resistance on the XBI at $90. There was some good news coming.

Mar 12, 2019 by Dave Sobek

March 12 Biotech Update

I am finally back and the sector appears to have pulled back a little. I do not see this a particularly bad pull back as it looks to have closed.

Feb 28, 2019 by Dave Sobek

February 28th Biotech Update

The sector continues to hang out at these levels and my sense is that the longer we wait to go, the more likely we consolidate the move higher. I do.

Feb 27, 2019 by Dave Sobek

February 27 Biotech Update

We still have not gapped and went, so I would think that possibility is lowering but I would not completely discount it. We have some positive news today in the.

More From All Reports

Introduction


Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More